Outsourcing

Jim Miller is president of PharmSource Information Services, Inc., and publisher of Bio/Pharmaceutical Outsourcing Report.

Articles

As manufacturers move to manufacture to demand rather than to forecast, the traditional wholesaling business model is being transformed.

New Supply-Chain Dynamics

Exhibitors at October's AAPS meeting confirmed that the demand for services is robust and believe that the industry's pipeline appears stronger than it has been in the past few years.

All Signs Indicate a Strong 2004 for Contract Services

As FDA tries to bring pharmaceutical manufacturing into the 21st century, competitive dynamics in contract manufacturing are likely to change in favor of companies that have greater manufacturing expertise and the means to invest in new technologies.

FDA Will Drive Changes for Contract Business

Outsourcing is part of the public debate as politicians seek to explain the lag in job growth despite a recovering economy, and as the Bush administration presses its initiative to "competitively source" more agency activities.

Outsourcing is Front Page News in 2003

CROs and contract manufacturers had a decent second quarter, but they are hoping that Big Pharma comes through with a burst of trial start-ups in the second half of 2003.

CROs Hoping for Research Burst in Second Half of 2003

The Biotechnology Industry Organization lends insight into the trends of biopharmaceutical contract manufacturing.

BIO Update

This second annual survey tracks teh growth of the outsourcing services sector in the past year.

Survey Finds Outsourcing Practice Continuing to Mature

The DSM investment puts biomanufacturing capacity in the spotlight. Contract biomanufacturers are adding new capacity and sponsors are marketing their excess capacity.

Capacity Worries Fade for Biomanufacturing

Gene Logic acquires TherImmune Research Corp. as part of its plan to create a new business model; First quarter results are a mixed bag for contract services companies.

Outsourcing Outlook

The successful auction of Quintiles raises questions for the company's new owners, Pharma Services Holdings, Inc., and the entire pharmaceutical industry with regard to strategic investments, assets to be sold, and other concerns.